Lyell Immunopharma Inc. (LYEL)
Lyell Immunopharma Statistics
Share Statistics
Lyell Immunopharma has 295.28M shares outstanding. The number of shares has increased by 15.8% in one year.
| Shares Outstanding | 295.28M |
| Shares Change (YoY) | 15.8% |
| Shares Change (QoQ) | 1.05% |
| Owned by Institutions (%) | 58.63% |
| Shares Floating | 124.86M |
| Failed to Deliver (FTD) Shares | 486 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 5.71M, so 1.93% of the outstanding shares have been sold short.
| Short Interest | 5.71M |
| Short % of Shares Out | 1.93% |
| Short % of Float | 2.6% |
| Short Ratio (days to cover) | 5.79 |
Valuation Ratios
The PE ratio is -0.49 and the forward PE ratio is -0.7. Lyell Immunopharma's PEG ratio is -0.01.
| PE Ratio | -0.49 |
| Forward PE | -0.7 |
| PS Ratio | 2743.4 |
| Forward PS | 2509.2 |
| PB Ratio | 0.44 |
| P/FCF Ratio | -1.03 |
| PEG Ratio | -0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Lyell Immunopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.06, with a Debt / Equity ratio of 0.13.
| Current Ratio | 7.06 |
| Quick Ratio | 7.06 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | -15.41 |
| Debt / FCF | -0.31 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $203.33 |
| Profits Per Employee | $-1.14M |
| Employee Count | 300 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -81.15% in the last 52 weeks. The beta is -0.27, so Lyell Immunopharma's price volatility has been lower than the market average.
| Beta | -0.27 |
| 52-Week Price Change | -81.15% |
| 50-Day Moving Average | 0.57 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 44.22 |
| Average Volume (20 Days) | 1.01M |
Income Statement
In the last 12 months, Lyell Immunopharma had revenue of 61K and earned -342.99M in profits. Earnings per share was -1.31.
| Revenue | 61K |
| Gross Profit | 61K |
| Operating Income | -3.31M |
| Net Income | -342.99M |
| EBITDA | -3.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.31 |
Balance Sheet
The company has 105.6M in cash and 50.99M in debt, giving a net cash position of 54.6M.
| Cash & Cash Equivalents | 105.6M |
| Total Debt | 50.99M |
| Net Cash | 54.6M |
| Retained Earnings | -1.35B |
| Total Assets | 490.86M |
| Working Capital | 325.81M |
Cash Flow
In the last 12 months, operating cash flow was -162.39M and capital expenditures -464K, giving a free cash flow of -162.86M.
| Operating Cash Flow | -162.39M |
| Capital Expenditures | -464K |
| Free Cash Flow | -162.86M |
| FCF Per Share | -0.62 |
Margins
Gross margin is 100%, with operating and profit margins of -5424.59% and -562285.25%.
| Gross Margin | 100% |
| Operating Margin | -5424.59% |
| Pretax Margin | -562285.25% |
| Profit Margin | -562285.25% |
| EBITDA Margin | -5424.59% |
| EBIT Margin | -5424.59% |
| FCF Margin | -266980.33% |
Dividends & Yields
LYEL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LYEL is $1, which is 117.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $1 |
| Price Target Difference | 117.4% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -3.81 |
| Piotroski F-Score | 2 |